Isomorphic Labs AI Drug Design (DeepMind Spinoff)

Isomorphic Labs, DeepMind's commercial spinout, applies AlphaFold-derived artificial intelligence to the pharmaceutical drug discovery pipeline, operating from its London headquarters with a Swiss presence in the Lausanne/Zurich corridor connecting to EPFL and ETH Zurich. The company builds on AlphaFold's protein structure prediction breakthrough to develop AI systems addressing multiple stages of drug discovery: target identification, molecular design, property prediction, and clinical optimization. Isomorphic's molecular design platform uses generative AI models trained on known molecular structures and biological activity measurements to propose novel compounds optimized for specific therapeutic targets. Multi-property optimization ensures designed molecules satisfy constraints across binding affinity, tissue concentration, toxicity, stability, and manufacturability simultaneously. The company has announced major pharmaceutical partnerships with Eli Lilly and Novartis, deploying its AI platform against targets identified by these partners. Switzerland's pharmaceutical ecosystem—anchored by Novartis and Roche in Basel and reinforced by ETH Zurich's AI research excellence—provides both talent and collaborative opportunities for Isomorphic's Swiss-connected research activities.